A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for optimally debulked primary ovarian cancer: The TRIO14 trial.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Gottfried E. Konecny, Paul Haluska, Fritz Janicke, Jalid Sehouli, Matthias W. Beckmann, Gabriele Feisel, Martin Pölcher, Lynda Roman, Achim Rody, Beth Karlan, Isabelle Laure Ray-Coquard, Diane M. Provencher, Noa Ben-Baruch, Paul H. Cottu, Hsiao-Wang Chen, Chen Wang, Judy Dering, Sylvie Jacod, Vincent Houe, Dennis J. Slamon
Institutions: University of California, Los Angeles, Mayo Clinic, University Medical Center Hamburg-Eppendorf, Charité - Universitätsmedizin Berlin, Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum Kassel, University of Bonn, University Hospital Bonn, USC Norris Comprehensive Cancer Center, Universitätsklinikum des Saarlandes, Cedars-Sinai Medical Center, Centre Léon Bérard, Kaplan Medical Center, Institut Curie, Translational Research in Oncology
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2605227591